Lipocine announces financial results for the second quarter ended june 30, 2024

Salt lake city , aug. 8, 2024 /prnewswire/ -- lipocine inc. (nasdaq: lpcn), a biopharmaceutical company leveraging its proprietary technology platform to augment therapeutics through effective oral delivery, today announced financial results for the second quarter ended june 30, 2024 and provided a corporate update. lpcn 1154 for postpartum depression (ppd) in june 2024, lipocine announced positive topline study results from the nda enabling study of lpcn 1154.
LPCN Ratings Summary
LPCN Quant Ranking